Rezafungin
Product Description
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
Country/Region:India
-
On CPHI since:2020
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
Categories
Specifications
OMGENE LIFE SCIENCES PRIVATE LIMITED
-
Country/Region:India
-
On CPHI since:2020
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)
-
Product Triptorelin Acetate
For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination.
-
Product Vasopressin
Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. -
Product Vismodegib
Indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. -
Product Complex Semi-synthetic APIs
Micafungin Sodium, Anidulafungin-Fructose, Dalbavancin, Everolimus, Sarecycline, Midostaurin etc. -
Product Omadacycline
A tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms (1): Community-acquired bacterial pneumonia (CABP) (1.1); Acute bacterial skin and skin structure infections (ABSSSI) -
Product Tirzepatide
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-
Product Cetrorelix Acetate
Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. -
Product Degarelix Acetate
Indicated for treatment of patients with advanced prostate cancer. -
Product Apremilast
Indicated in Psoriatic Arthritis, Psoriasis and Oral Ulcers Associated with Behçet’s Disease -
Product Bedaquiline Fumarate
Diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). -
Product Binimetinib
Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation











